The Role of M6A Modification in the Biological Functions and Diseases

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2021 Feb 21

PMID 33611339

Citations 692

Authors

Xiulin Jiang

Baiyang Liu

Zhi Nie

Lincan Duan

Qiuxia Xiong

Zhixian Jin

Cuiping Yang

Yongbin Chen

Affiliations

Soon will be listed here.

Abstract

N-methyladenosine (m6A) is the most prevalent, abundant and conserved internal cotranscriptional modification in eukaryotic RNAs, especially within higher eukaryotic cells. m6A modification is modified by the m6A methyltransferases, or writers, such as METTL3/14/16, RBM15/15B, ZC3H3, VIRMA, CBLL1, WTAP, and KIAA1429, and, removed by the demethylases, or erasers, including FTO and ALKBH5. It is recognized by m6A-binding proteins YTHDF1/2/3, YTHDC1/2 IGF2BP1/2/3 and HNRNPA2B1, also known as "readers". Recent studies have shown that m6A RNA modification plays essential role in both physiological and pathological conditions, especially in the initiation and progression of different types of human cancers. In this review, we discuss how m6A RNA methylation influences both the physiological and pathological progressions of hematopoietic, central nervous and reproductive systems. We will mainly focus on recent progress in identifying the biological functions and the underlying molecular mechanisms of m6A RNA methylation, its regulators and downstream target genes, during cancer progression in above systems. We propose that m6A RNA methylation process offer potential targets for cancer therapy in the future.

Citing Articles

A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members.

Zeng F, Chen L, Li J, Yu W, Sa N, Zhang K Discov Oncol. 2025; 16(1):323.

PMID: 40088376 DOI: 10.1007/s12672-025-02077-2.

YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells.

Gao M, Wu Y, Zhang L, Zhou Y, Liu H, Zhang W Sci Rep. 2025; 15(1):8857.

PMID: 40087295 DOI: 10.1038/s41598-025-92925-6.

The Role of MA Modification in Autoimmunity: Emerging Mechanisms and Therapeutic Implications.

Xu L, Shen T, Li Y, Wu X Clin Rev Allergy Immunol. 2025; 68(1):29.

PMID: 40085180 DOI: 10.1007/s12016-025-09041-6.

N6-methyadenosine-modified YWHAE mRNA promotes proliferation and inhibits ferroptosis in hepatoblastoma by mediating SLC7A11 expression.

Zhou J, Wang J, Yang L, Fu T, Li H, Shan Y Oncogene. 2025; .

PMID: 40074884 DOI: 10.1038/s41388-025-03334-y.

mA transferase KIAA1429 mediates the upregulation of LncRNA LINC00968 promoting the progression of gastric cancer cells.

Liu H, Yang M, Zhang C, Zhang Y, Wang Y, Chen Y Hereditas. 2025; 162(1):34.

PMID: 40069867 PMC: 11895323. DOI: 10.1186/s41065-025-00393-9.

References

Jones P, Issa J, Baylin S . Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016; 17(10):630-41. DOI: 10.1038/nrg.2016.93. View

Liu H, Begik O, Lucas M, Ramirez J, Mason C, Wiener D . Accurate detection of mA RNA modifications in native RNA sequences. Nat Commun. 2019; 10(1):4079. PMC: 6734003. DOI: 10.1038/s41467-019-11713-9. View

Liu N, Pan T . N6-methyladenosine–encoded epitranscriptomics. Nat Struct Mol Biol. 2016; 23(2):98-102. DOI: 10.1038/nsmb.3162. View

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View

Yang Y, Hsu P, Chen Y, Yang Y . Dynamic transcriptomic mA decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018; 28(6):616-624. PMC: 5993786. DOI: 10.1038/s41422-018-0040-8. View

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S . Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012; 485(7397):201-6. DOI: 10.1038/nature11112. View

Meyer K, Saletore Y, Zumbo P, Elemento O, Mason C, Jaffrey S . Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell. 2012; 149(7):1635-46. PMC: 3383396. DOI: 10.1016/j.cell.2012.05.003. View

Chen K, Lu Z, Wang X, Fu Y, Luo G, Liu N . High-resolution N(6) -methyladenosine (m(6) A) map using photo-crosslinking-assisted m(6) A sequencing. Angew Chem Int Ed Engl. 2014; 54(5):1587-90. PMC: 4396828. DOI: 10.1002/anie.201410647. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

10.

Ke S, Alemu E, Mertens C, Gantman E, Fak J, Mele A . A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev. 2015; 29(19):2037-53. PMC: 4604345. DOI: 10.1101/gad.269415.115. View

11.

Li X, Xiong X, Yi C . Epitranscriptome sequencing technologies: decoding RNA modifications. Nat Methods. 2016; 14(1):23-31. DOI: 10.1038/nmeth.4110. View

12.

Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

13.

Schwartz S, Agarwala S, Mumbach M, Jovanovic M, Mertins P, Shishkin A . High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell. 2013; 155(6):1409-21. PMC: 3956118. DOI: 10.1016/j.cell.2013.10.047. View

14.

Harcourt E, Ehrenschwender T, Batista P, Chang H, Kool E . Identification of a selective polymerase enables detection of N(6)-methyladenosine in RNA. J Am Chem Soc. 2013; 135(51):19079-82. PMC: 3905807. DOI: 10.1021/ja4105792. View

15.

Wang S, Wang J, Zhang X, Fu B, Song Y, Ma P . -Methyladenine hinders RNA- and DNA-directed DNA synthesis: application in human rRNA methylation analysis of clinical specimens. Chem Sci. 2018; 7(2):1440-1446. PMC: 5975930. DOI: 10.1039/c5sc02902c. View

16.

Shu X, Dai Q, Wu T, Bothwell I, Yue Y, Zhang Z . N-Allyladenosine: A New Small Molecule for RNA Labeling Identified by Mutation Assay. J Am Chem Soc. 2017; 139(48):17213-17216. PMC: 5813804. DOI: 10.1021/jacs.7b06837. View

17.

Hong T, Yuan Y, Chen Z, Xi K, Wang T, Xie Y . Precise Antibody-Independent m6A Identification via 4SedTTP-Involved and FTO-Assisted Strategy at Single-Nucleotide Resolution. J Am Chem Soc. 2018; 140(18):5886-5889. DOI: 10.1021/jacs.7b13633. View

18.

Zhang Z, Chen L, Zhao Y, Yang C, Roundtree I, Zhang Z . Single-base mapping of mA by an antibody-independent method. Sci Adv. 2019; 5(7):eaax0250. PMC: 6609220. DOI: 10.1126/sciadv.aax0250. View

19.

Garcia-Campos M, Edelheit S, Toth U, Safra M, Shachar R, Viukov S . Deciphering the "mA Code" via Antibody-Independent Quantitative Profiling. Cell. 2019; 178(3):731-747.e16. DOI: 10.1016/j.cell.2019.06.013. View

20.

Meyer K . DART-seq: an antibody-free method for global mA detection. Nat Methods. 2019; 16(12):1275-1280. PMC: 6884681. DOI: 10.1038/s41592-019-0570-0. View